المؤلفون: Baker TK; Investigative Toxicology, Eli Lilly, Indianapolis, Indiana (T.K.B.); Investigative Toxicology and Pathology, AbbVie, Inc., Chicago, Illinois (T.R.V.F., P.K.M.); Complex In Vitro Models Group, GSK, Collegeville, Pennsylvania (T.S.P.G.); Preclinical Sciences and Translational Safety, Johnson & Johnson, Janssen Pharmaceuticals, Spring House, Pennsylvania (R.E.); UCB Pharma, Cambridge, Massachusetts (J.E.); Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Pfizer, Inc., Cambridge, Massachusetts (J.R.G.); Research and Development, Bristol Myers Squibb Company, Princeton, New Jersey (S.A.C.); and Drug Safety Research & Development, Pfizer, Inc., Groton, Connecticut (A.K.K.) baker_thomas_k@lilly., Van Vleet TR; Investigative Toxicology, Eli Lilly, Indianapolis, Indiana (T.K.B.); Investigative Toxicology and Pathology, AbbVie, Inc., Chicago, Illinois (T.R.V.F., P.K.M.); Complex In Vitro Models Group, GSK, Collegeville, Pennsylvania (T.S.P.G.); Preclinical Sciences and Translational Safety, Johnson & Johnson, Janssen Pharmaceuticals, Spring House, Pennsylvania (R.E.); UCB Pharma, Cambridge, Massachusetts (J.E.); Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Pfizer, Inc., Cambridge, Massachusetts (J.R.G.); Research and Development, Bristol Myers Squibb Company, Princeton, New Jersey (S.A.C.); and Drug Safety Research & Development, Pfizer, Inc., Groton, Connecticut (A.K.K.)., Mahalingaiah PK; Investigative Toxicology, Eli Lilly, Indianapolis, Indiana (T.K.B.); Investigative Toxicology and Pathology, AbbVie, Inc., Chicago, Illinois (T.R.V.F., P.K.M.); Complex In Vitro Models Group, GSK, Collegeville, Pennsylvania (T.S.P.G.); Preclinical Sciences and Translational Safety, Johnson & Johnson, Janssen Pharmaceuticals, Spring House, Pennsylvania (R.E.); UCB Pharma, Cambridge, Massachusetts (J.E.); Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Pfizer, Inc., Cambridge, Massachusetts (J.R.G.); Research and Development, Bristol Myers Squibb Company, Princeton, New Jersey (S.A.C.); and Drug Safety Research & Development, Pfizer, Inc., Groton, Connecticut (A.K.K.)., Grandhi TSP; Investigative Toxicology, Eli Lilly, Indianapolis, Indiana (T.K.B.); Investigative Toxicology and Pathology, AbbVie, Inc., Chicago, Illinois (T.R.V.F., P.K.M.); Complex In Vitro Models Group, GSK, Collegeville, Pennsylvania (T.S.P.G.); Preclinical Sciences and Translational Safety, Johnson & Johnson, Janssen Pharmaceuticals, Spring House, Pennsylvania (R.E.); UCB Pharma, Cambridge, Massachusetts (J.E.); Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Pfizer, Inc., Cambridge, Massachusetts (J.R.G.); Research and Development, Bristol Myers Squibb Company, Princeton, New Jersey (S.A.C.); and Drug Safety Research & Development, Pfizer, Inc., Groton, Connecticut (A.K.K.)., Evers R; Investigative Toxicology, Eli Lilly, Indianapolis, Indiana (T.K.B.); Investigative Toxicology and Pathology, AbbVie, Inc., Chicago, Illinois (T.R.V.F., P.K.M.); Complex In Vitro Models Group, GSK, Collegeville, Pennsylvania (T.S.P.G.); Preclinical Sciences and Translational Safety, Johnson & Johnson, Janssen Pharmaceuticals, Spring House, Pennsylvania (R.E.); UCB Pharma, Cambridge, Massachusetts (J.E.); Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Pfizer, Inc., Cambridge, Massachusetts (J.R.G.); Research and Development, Bristol Myers Squibb Company, Princeton, New Jersey (S.A.C.); and Drug Safety Research & Development, Pfizer, Inc., Groton, Connecticut (A.K.K.)., Ekert J; Investigative Toxicology, Eli Lilly, Indianapolis, Indiana (T.K.B.); Investigative Toxicology and Pathology, AbbVie, Inc., Chicago, Illinois (T.R.V.F., P.K.M.); Complex In Vitro Models Group, GSK, Collegeville, Pennsylvania (T.S.P.G.); Preclinical Sciences and Translational Safety, Johnson & Johnson, Janssen Pharmaceuticals, Spring House, Pennsylvania (R.E.); UCB Pharma, Cambridge, Massachusetts (J.E.); Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Pfizer, Inc., Cambridge, Massachusetts (J.R.G.); Research and Development, Bristol Myers Squibb Company, Princeton, New Jersey (S.A.C.); and Drug Safety Research & Development, Pfizer, Inc., Groton, Connecticut (A.K.K.)., Gosset JR; Investigative Toxicology, Eli Lilly, Indianapolis, Indiana (T.K.B.); Investigative Toxicology and Pathology, AbbVie, Inc., Chicago, Illinois (T.R.V.F., P.K.M.); Complex In Vitro Models Group, GSK, Collegeville, Pennsylvania (T.S.P.G.); Preclinical Sciences and Translational Safety, Johnson & Johnson, Janssen Pharmaceuticals, Spring House, Pennsylvania (R.E.); UCB Pharma, Cambridge, Massachusetts (J.E.); Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Pfizer, Inc., Cambridge, Massachusetts (J.R.G.); Research and Development, Bristol Myers Squibb Company, Princeton, New Jersey (S.A.C.); and Drug Safety Research & Development, Pfizer, Inc., Groton, Connecticut (A.K.K.)., Chacko SA; Investigative Toxicology, Eli Lilly, Indianapolis, Indiana (T.K.B.); Investigative Toxicology and Pathology, AbbVie, Inc., Chicago, Illinois (T.R.V.F., P.K.M.); Complex In Vitro Models Group, GSK, Collegeville, Pennsylvania (T.S.P.G.); Preclinical Sciences and Translational Safety, Johnson & Johnson, Janssen Pharmaceuticals, Spring House, Pennsylvania (R.E.); UCB Pharma, Cambridge, Massachusetts (J.E.); Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Pfizer, Inc., Cambridge, Massachusetts (J.R.G.); Research and Development, Bristol Myers Squibb Company, Princeton, New Jersey (S.A.C.); and Drug Safety Research & Development, Pfizer, Inc., Groton, Connecticut (A.K.K.)., Kopec AK; Investigative Toxicology, Eli Lilly, Indianapolis, Indiana (T.K.B.); Investigative Toxicology and Pathology, AbbVie, Inc., Chicago, Illinois (T.R.V.F., P.K.M.); Complex In Vitro Models Group, GSK, Collegeville, Pennsylvania (T.S.P.G.); Preclinical Sciences and Translational Safety, Johnson & Johnson, Janssen Pharmaceuticals, Spring House, Pennsylvania (R.E.); UCB Pharma, Cambridge, Massachusetts (J.E.); Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Pfizer, Inc., Cambridge, Massachusetts (J.R.G.); Research and Development, Bristol Myers Squibb Company, Princeton, New Jersey (S.A.C.); and Drug Safety Research & Development, Pfizer, Inc., Groton, Connecticut (A.K.K.).

المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Feb 14; Vol. 52 (3), pp. 198-209. Date of Electronic Publication: 2024 Feb 14.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE

مواضيع طبية MeSH: Microphysiological Systems* , Drug Industry*, Animals ; Humans ; Drug Discovery

المؤلفون: Stresser DM; Quantitative, Translational & ADME Sciences, AbbVie, North Chicago, IL, USA. david.stresser@abbvie.com.; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ), . david.stresser@abbvie.com.; IQ Microphysiological Systems Affiliate (IQ-), . david.stresser@abbvie.com., Kopec AK; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Drug Safety Research & Development, Pfizer, Inc., Groton, CT, USA., Hewitt P; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Chemical and Preclinical Safety, Merck KGaA, Darmstadt, Germany., Hardwick RN; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Discovery Toxicology, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, San Diego, CA, USA., Van Vleet TR; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Investigative Toxicology and Pathology, AbbVie, North Chicago, IL, USA., Mahalingaiah PKS; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Investigative Toxicology and Pathology, AbbVie, North Chicago, IL, USA., O'Connell D; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; Global Animal Welfare, AbbVie, North Chicago, IL, USA.; IQ 3Rs (Replacement, Reduction, Refinement) Translational and Predictive Sciences Leadership Group., Jenkins GJ; Quantitative, Translational & ADME Sciences, AbbVie, North Chicago, IL, USA.; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Translational and ADME Sciences Leadership Group (TALG)., David R; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Clinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, UK., Graham J; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; Product Quality & Occupational Toxicology, Genentech, Inc., South San Francisco, CA, USA.; IQ DruSafe.; Safety Assessment, Genentech, Inc., South San Francisco, CA, USA., Lee D; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ 3Rs (Replacement, Reduction, Refinement) Translational and Predictive Sciences Leadership Group.; Safety Assessment, Genentech, Inc., South San Francisco, CA, USA., Ekert J; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; UCB Pharma, Cambridge, MA, USA., Fullerton A; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Investigative Toxicology, Genentech, Inc., South San Francisco, CA, USA., Villenave R; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Bajaj P; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Global Investigative Toxicology, Preclinical Safety, Sanofi, Cambridge, MA, USA., Gosset JR; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Pfizer, Inc, Cambridge, MA, USA., Ralston SL; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ 3Rs (Replacement, Reduction, Refinement) Translational and Predictive Sciences Leadership Group.; Preclinical Safety, AbbVie, North Chicago, IL, USA., Guha M; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Discovery Biology, Incyte, Wilmington, DE, USA., Amador-Arjona A; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Discovery Biology, Incyte, Wilmington, DE, USA., Khan K; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Clinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, UK., Agarwal S; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Investigative Toxicology, Early Development, Alnylam Pharmaceuticals, Cambridge, MA, USA., Hasselgren C; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ DruSafe.; Predictive Toxicology, Genentech, Inc., South San Francisco, CA, USA., Wang X; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Translational Safety & Bioanalytical Sciences, Amgen Research, Amgen Inc., South San Francisco, CA, USA., Adams K; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ 3Rs (Replacement, Reduction, Refinement) Translational and Predictive Sciences Leadership Group.; Laboratory Animal Resources, Incyte, Wilmington, DE, USA., Kaushik G; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Nonclinical Drug Safety, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA., Raczynski A; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Preclinical Safety Assessment, Vertex Pharmaceuticals, Inc, Boston, MA, USA., Homan KA; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ), . homan.kimberly@gene.com.; IQ Microphysiological Systems Affiliate (IQ-), . homan.kimberly@gene.com.; Complex in vitro Systems Group, Genentech, Inc., South San Francisco, CA, USA. homan.kimberly@gene.com.

المصدر: Nature biomedical engineering [Nat Biomed Eng] 2023 Dec 27. Date of Electronic Publication: 2023 Dec 27.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Nature Country of Publication: England NLM ID: 101696896 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2157-846X (Electronic) Linking ISSN: 2157846X NLM ISO Abbreviation: Nat Biomed Eng Subsets: MEDLINE

المؤلفون: Tomlinson L; Global Pathology, Pfizer Inc., Cambridge, MA, 02140, USA., Ramsden D; DMPK Oncology, AstraZeneca, Boston, MA, 02451, USA., Leite SB; European Commission Joint Research Centre, Ispra, 21027, Italy., Beken S; Federal Agency for Medicines and Health Products, Brussels, 1210, Belgium., Bonzo JA; Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Brown P; Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Candarlioglu PL; Complex In Vitro Models, GSK, Stevenage, SG1 2NY, UK., Chan TS; Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 06877, USA., Chen E; DMPK, Genentech, South San Francisco, CA, 94080, USA., Choi CK; Preclinical Safety, Biogen, Cambridge, MA, 02142, USA., David R; Clinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, CB2 0AA, UK., Delrue N; Organisation for Economic Co-operation and Development, Paris, 75016, France., Devine PJ; Discovery Toxicology, Bristol Myers Squibb, San Diego, CA, 09130, USA., Ford K; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Garcia MI; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Gosset JR; DMPK, Pfizer Inc., Cambridge, MA, 02139, USA., Hewitt P; Chemical and Preclinical Safety, Merck Healthcare KGaA, 64293, Darmstadt, Germany., Homan K; Complex in Vitro Systems Group, Genentech, South San Francisco, CA, 94080, USA., Irrechukwu O; Preclinical Sciences and Translational Safety, Johnson and Johnson Innovation Medicine, Spring House, PA, 19002, USA., Kopec AK; Drug Safety Research & Development, Pfizer Inc., Groton, CT, 06340, USA., Liras JL; Pharmacokinetics, Dynamics & Metabolism-Medicine Design, Pfizer, Cambridge, MA, 02139, USA., Mandlekar S; Clinical Pharmacology, Genentech, South San Francisco, CA, 94080, USA., Raczynski A; Preclinical Safety Assessment, Vertex Pharmaceuticals Inc., Boston, MA, 02210, USA., Sadrieh N; Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Sakatis MZ; Non-Clinical Safety, In Vitro/In Vivo Translation, GSK R&D, Ware, SG12 9TJ, UK., Siegel J; Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Sung K; Center for Biologics Evaluation and Research, Office of Cellular Therapy and Human Tissue, Cellular and Tissue Therapy Branch, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Sunyovszki I; Translational Cellular Sciences, Biogen, Cambridge, MA, 02142, USA., Van Vleet TR; AbbVie, Inc., North Chicago, IL, 60064, USA., Ekert JE; UCB Pharma, Cambridge, MA, 02140, USA., Hardwick RN; Discovery Toxicology, Bristol Myers Squibb, San Diego, CA, 09130, USA.

المصدر: Advanced biology [Adv Biol (Weinh)] 2023 Oct 09, pp. e2300131. Date of Electronic Publication: 2023 Oct 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley-VCH GmbH Country of Publication: Germany NLM ID: 101775319 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2701-0198 (Electronic) Linking ISSN: 27010198 NLM ISO Abbreviation: Adv Biol (Weinh) Subsets: MEDLINE

المؤلفون: Wang X; Translational Safety & Bioanalytical Sciences, Amgen Research, Amgen, Inc., South San Francisco, CA, USA., Kopec AK; Drug Safety Research & Development, Pfizer, Inc., Groton, CT, USA., Collinge M; Drug Safety Research & Development, Pfizer, Inc., Groton, CT, USA., David R; Safety Innovation, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK., Grant C; Preclinical Safety, AbbVie, Inc., Worcester, MA, USA., Hardwick RN; Translational Safety Sciences, Theravance Biopharma US, Inc., South San Francisco, CA, USA.; current affiliation: Discovery Toxicology, Preclinical Candidate Optimization, Bristol Myers Squibb, San Diego, CA, USA., Navratil A; Biology and Pharmacology, Theravance Biopharma US, Inc., South San Francisco, CA, USA., Patel N; Preclinical Safety, Research and Development, Sanofi-Aventis US, LLC, Framingham, MA, USA., Rowan W; Novel Human Genetics, GSK, Stevenage, UK., Marshall N; Non-Clinical Safety, GSK, Collegeville, PA, USA.

المصدر: ALTEX [ALTEX] 2022 Aug 29; Vol. 40 (2), pp. 314–336. Date of Electronic Publication: 2022 Aug 29.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Spektrum Akademischer Verlag Country of Publication: Germany NLM ID: 100953980 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1868-8551 (Electronic) Linking ISSN: 1868596X NLM ISO Abbreviation: ALTEX Subsets: MEDLINE

المؤلفون: Poole LG; Department of Pathobiology & Diagnostic Investigation, Michigan State University, East Lansing, Michigan, USA.; Institute for Integrative Toxicology, Michigan State University, East Lansing, Michigan, USA., Kopec AK; Department of Pathobiology & Diagnostic Investigation, Michigan State University, East Lansing, Michigan, USA.; Institute for Integrative Toxicology, Michigan State University, East Lansing, Michigan, USA., Flick MJ; Department of Pathology and Laboratory Medicine, UNC Blood Research Center, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Luyendyk JP; Department of Pathobiology & Diagnostic Investigation, Michigan State University, East Lansing, Michigan, USA.; Institute for Integrative Toxicology, Michigan State University, East Lansing, Michigan, USA.; Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, USA.

المصدر: Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2022 May; Vol. 20 (5), pp. 1182-1192. Date of Electronic Publication: 2022 Feb 27.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 101170508 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7836 (Electronic) Linking ISSN: 15387836 NLM ISO Abbreviation: J Thromb Haemost Subsets: MEDLINE

مواضيع طبية MeSH: Lipopolysaccharides* , Protein Glutamine gamma Glutamyltransferase 2*, Animals ; Fibrin/metabolism ; Fibrinogen/metabolism ; Humans ; Macrophages/metabolism ; Mice ; Transglutaminases/genetics ; Transglutaminases/metabolism ; Tumor Necrosis Factor-alpha

المؤلفون: Baran SW; Emerging Technologies, Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Brown PC; U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drugs, Silver Spring, MD, USA., Baudy AR; ADME & Discovery Toxicology, Merck & Co., Inc., Kenilworth, NJ, USA., Fitzpatrick SC; U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of the Center Director, College Park, MD, USA., Frantz C; Translational Sciences, Seagen, Seattle, WA, USA., Fullerton A; Safety Assessment, Genentech, South San Francisco, CA, USA., Gan J; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, Princeton, NJ, USA., Hardwick RN; Translational Safety Sciences, Theravance Biopharma US, Inc., South San Francisco, CA, USA., Hillgren KM; Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA., Kopec AK; Drug Safety Research & Development, Pfizer, Inc., Groton, CT, USA., Liras JL; Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Cambridge, MA, USA., Mendrick DL; U.S. Food and Drug Administration, National Center for Toxicological Research, Office of the Center Director, Silver Spring, MD, USA., Nagao R; Translational Sciences, Seagen, Seattle, WA, USA., Proctor WR; Safety Assessment, Genentech, South San Francisco, CA, USA., Ramsden D; Global Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co., Cambridge, MA, USA., Ribeiro AJS; U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Translational Sciences, Office of Clinical Pharmacology, Division of Applied Regulatory Science, Silver Spring, MD, USA., Stresser D; Drug Metabolism, Pharmacokinetics and Bioanalysis, AbbVie, Inc., North Chicago, IL, USA., Sung KE; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Tissues and Advanced Therapies, Division of Cellular and Gene Therapies, Silver Spring, MD, USA., Sura R; Global Preclinical Safety, AbbVie Inc., North Chicago, IL, USA., Tetsuka K; Analysis & Pharmacokinetics Research Labs., Astellas Pharma Inc., Tsukuba-shi, Ibaraki, Japan., Tomlinson L; Global Pathology, DSRD, Pfizer WRD, Cambridge, MA, USA., Van Vleet T; AbbVie, Inc., Chicago, IL, USA., Wagoner MP; Drug Safety Research & Evaluation, Takeda Pharmaceuticals International Co., Cambridge, MA, USA., Wang Q; Drug Safety Research & Evaluation, Takeda Pharmaceuticals International Co., Cambridge, MA, USA., Arslan SY; BioAnalysis, Applied Research Management & Biomedical Science (AMS), Astellas Pharma Inc., Northbrook, IL, USA., Yoder G; Aimmune (Nestlé Health Sciences), Brisbane, CA, USA., Ekert JE; In Vitro In Vivo Translation, Research, Pharmaceutical R&D, GlaxoSmithKline, Collegeville, PA, USA.

المصدر: ALTEX [ALTEX] 2022; Vol. 39 (2), pp. 297–314. Date of Electronic Publication: 2022 Jan 21.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Spektrum Akademischer Verlag Country of Publication: Germany NLM ID: 100953980 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1868-8551 (Electronic) Linking ISSN: 1868596X NLM ISO Abbreviation: ALTEX Subsets: MEDLINE

مواضيع طبية MeSH: Animal Testing Alternatives* , Lab-On-A-Chip Devices*, Animals ; Drug Evaluation, Preclinical ; Drug Industry ; Pharmaceutical Preparations/metabolism ; United States ; United States Food and Drug Administration

المؤلفون: Poole LG; Department of Pathobiology & Diagnostic Investigation, Michigan State University, East Lansing, MI, USA; Institute for Integrative Toxicology, Michigan State University, East Lansing, MI, USA., Fournier AK; Department of Pathobiology & Diagnostic Investigation, Michigan State University, East Lansing, MI, USA., Cline-Fedewa HM; Department of Pathobiology & Diagnostic Investigation, Michigan State University, East Lansing, MI, USA., Kopec AK; Department of Pathobiology & Diagnostic Investigation, Michigan State University, East Lansing, MI, USA; Institute for Integrative Toxicology, Michigan State University, East Lansing, MI, USA., Luyendyk JP; Department of Pathobiology & Diagnostic Investigation, Michigan State University, East Lansing, MI, USA; Institute for Integrative Toxicology, Michigan State University, East Lansing, MI, USA; Department of Pharmacology & Toxicology, Michigan State University, East Lansing, MI, USA., Groeneveld DJ; Department of Pathobiology & Diagnostic Investigation, Michigan State University, East Lansing, MI, USA. Electronic address: groene12@cvm.msu.edu.

المصدر: Toxicology [Toxicology] 2021 Nov; Vol. 463, pp. 152968. Date of Electronic Publication: 2021 Oct 04.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

بيانات الدورية: Publisher: Elsevier Country of Publication: Ireland NLM ID: 0361055 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-3185 (Electronic) Linking ISSN: 0300483X NLM ISO Abbreviation: Toxicology Subsets: MEDLINE

مواضيع طبية MeSH: Cholestasis/*physiopathology , Liver Cirrhosis/*physiopathology , von Willebrand Factor/*genetics, 1-Naphthylisothiocyanate ; Acute Disease ; Animals ; Blood Platelets/metabolism ; Cholestasis/genetics ; Chronic Disease ; Disease Models, Animal ; Female ; Liver Cirrhosis/genetics ; Mice ; Mice, Inbred C57BL ; Mice, Knockout

المؤلفون: Poole LG; Department of Pathobiology & Diagnostic Investigation.; Institute for Integrative Toxicology, and., Kopec AK; Department of Pathobiology & Diagnostic Investigation.; Institute for Integrative Toxicology, and., Groeneveld DJ; Department of Pathobiology & Diagnostic Investigation.; Institute for Integrative Toxicology, and., Pant A; Department of Pathobiology & Diagnostic Investigation.; Institute for Integrative Toxicology, and., Baker KS; Institute for Integrative Toxicology, and.; Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI; and., Cline-Fedewa HM; Department of Pathobiology & Diagnostic Investigation., Flick MJ; Department of Pathology and Laboratory Medicine, Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Luyendyk JP; Department of Pathobiology & Diagnostic Investigation.; Institute for Integrative Toxicology, and.; Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI; and.

المصدر: Blood [Blood] 2021 May 06; Vol. 137 (18), pp. 2520-2531.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Polymerization*, Chemical and Drug Induced Liver Injury/*pathology , Factor XIII/*physiology , Fibrin/*metabolism , Fibrinogen/*metabolism , Thrombin/*metabolism, Acetaminophen/toxicity ; Analgesics, Non-Narcotic/toxicity ; Animals ; Blood Coagulation ; Chemical and Drug Induced Liver Injury/etiology ; Chemical and Drug Induced Liver Injury/metabolism ; Fibrin/chemistry ; Fibrinogen/chemistry ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Knockout

المؤلفون: Harney J; Drug Safety Research and Development, Pfizer, Groton, CT, USA. Electronic address: Julie.Harney@pfizer.com., Bajaj P; Drug Safety Research and Development, Pfizer, Groton, CT, USA., Finley JE; Drug Safety Research and Development, Pfizer, Groton, CT, USA., Kopec AK; Drug Safety Research and Development, Pfizer, Groton, CT, USA., Koza-Taylor PH; Drug Safety Research and Development, Pfizer, Groton, CT, USA., Boucher GG; Drug Safety Research and Development, Pfizer, Groton, CT, USA., Lanz TA; Drug Safety Research and Development, Pfizer, Groton, CT, USA., Doshna CM; Drug Safety Research and Development, Pfizer, Groton, CT, USA., Somps CJ; Drug Safety Research and Development, Pfizer, Groton, CT, USA., Adkins K; Drug Safety Research and Development, Pfizer, Groton, CT, USA., Houle C; Drug Safety Research and Development, Pfizer, Groton, CT, USA.

المصدر: Toxicology in vitro : an international journal published in association with BIBRA [Toxicol In Vitro] 2021 Feb; Vol. 70, pp. 105012. Date of Electronic Publication: 2020 Oct 10.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Pergamon Press Country of Publication: England NLM ID: 8712158 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-3177 (Electronic) Linking ISSN: 08872333 NLM ISO Abbreviation: Toxicol In Vitro Subsets: MEDLINE

مواضيع طبية MeSH: Models, Biological*, Alveolar Epithelial Cells/*pathology , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/*antagonists & inhibitors, ATP-Binding Cassette Transporters/metabolism ; Adenocarcinoma of Lung/metabolism ; Alveolar Epithelial Cells/metabolism ; Alveolar Epithelial Cells/ultrastructure ; Cells, Cultured ; Drug Evaluation, Preclinical ; Gene Expression ; Humans ; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/genetics ; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/metabolism ; Lung Neoplasms/metabolism ; Pulmonary Surfactant-Associated Protein C/metabolism

المؤلفون: Kopec AK; Drug Safety Research & Development, Pfizer, Inc., CT, USA., Yokokawa R; Department of Micro Engineering, Kyoto University, Japan., Khan N; Drug Safety Research & Development, Pfizer, Inc., CT, USA., Horii I; Drug Safety Research & Development, Pfizer, Inc., Japan., Finley JE; Drug Safety Research & Development, Pfizer, Inc., CT, USA., Bono CP; Drug Safety Research & Development, Pfizer, Inc., CT, USA., Donovan C; Drug Safety Research & Development, Pfizer, Inc., CT, USA., Roy J; Drug Safety Research & Development, Pfizer, Inc., CT, USA., Harney J; Drug Safety Research & Development, Pfizer, Inc., CT, USA., Burdick AD; Drug Safety Research & Development, Pfizer, Inc., MA, USA., Jessen B; Drug Safety Research & Development, Pfizer, Inc., CA, USA., Lu S; Drug Safety Research & Development, Pfizer, Inc., CA, USA., Collinge M; Drug Safety Research & Development, Pfizer, Inc., CT, USA., Sadeghian RB; Department of Micro Engineering, Kyoto University, Japan., Derzi M; Drug Safety Research & Development, Pfizer, Inc., MA, USA., Tomlinson L; Drug Safety Research & Development, Pfizer, Inc., MA, USA., Burkhardt JE; Drug Safety Research & Development, Pfizer, Inc., CT, USA.

المصدر: The Journal of toxicological sciences [J Toxicol Sci] 2021; Vol. 46 (3), pp. 99-114.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Doku Sayō Kenkyūkai Country of Publication: Japan NLM ID: 7805798 Publication Model: Print Cited Medium: Internet ISSN: 1880-3989 (Electronic) Linking ISSN: 03881350 NLM ISO Abbreviation: J Toxicol Sci Subsets: MEDLINE

مواضيع طبية MeSH: Microfluidic Analytical Techniques* , Models, Biological*, Drug Development/*methods , Drug Development/*trends, Animals ; Biological Products ; Drug Industry ; Forecasting ; Humans ; Lab-On-A-Chip Devices